» Articles » PMID: 32674529

Evidence-based Clinical Advice for Nutrition and Dietary Weight Loss Strategies for the Management of NAFLD and NASH

Overview
Specialty Gastroenterology
Date 2020 Jul 18
PMID 32674529
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and affects approximately one third of adults in the United States. The disease is becoming a global epidemic as a result of the rising rates of obesity and metabolic disease. Emerging data suggest weight loss of ≥10% overall body weight is beneficial in resolving steatosis and reversing fibrosis. Prospective trials comparing various diets are limited by lack of sufficient power as well as pre- and post-treatment histopathology, and therefore no specific diet is recommended at this time. In this narrative review we examine the pathophysiology behind specific macronutrient components that can either promote or reverse NAFLD to help inform more specific dietary recommendations. Overall, the data supports reducing saturated fat, refined carbohydrates, and red and processed meats in the diet, and increasing the consumption of plant-based foods. Diets that incorporate these recommendations include plant-based diets such as the Dietary Approaches to Stop Hypertension, Mediterranean, vegetarian, and vegan diets.

Citing Articles

Effectiveness of RESET care program: A real-world-evidence on managing non-alcoholic fatty liver disease through digital health interventions.

Soni J, Pathak N, Gharia M, Aswal D, Parikh J, Sharma P World J Hepatol. 2025; 17(1):101630.

PMID: 39871911 PMC: 11736475. DOI: 10.4254/wjh.v17.i1.101630.


Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study.

Latif S, Ahsan T Euroasian J Hepatogastroenterol. 2025; 14(2):129-133.

PMID: 39802849 PMC: 11714111. DOI: 10.5005/jp-journals-10018-1437.


Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).

Do A, Zahrawi F, Mehal W Nat Rev Drug Discov. 2024; 24(3):171-189.

PMID: 39609545 DOI: 10.1038/s41573-024-01084-2.


Non-alcoholic fatty liver disease: The importance of physical activity and nutrition education-A randomized controlled study.

Us Altay D, Kaya Y, Mataraci Degirmenci D, Kocyigit E, Uner A, Noyan T J Gastroenterol Hepatol. 2024; 39(12):2723-2734.

PMID: 39343724 PMC: 11660201. DOI: 10.1111/jgh.16756.


Common Bean Suppresses Hepatic Ceramide Metabolism in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Fitzgerald V, Lutsiv T, McGinley J, Neil E, Playdon M, Thompson H Nutrients. 2024; 16(18).

PMID: 39339796 PMC: 11434909. DOI: 10.3390/nu16183196.


References
1.
Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L . Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019; 393(10170):434-445. DOI: 10.1016/S0140-6736(18)31809-9. View

2.
Aissa A, Tryndyak V, de Conti A, Melnyk S, Gomes T, Pires Bianchi M . Effect of methionine-deficient and methionine-supplemented diets on the hepatic one-carbon and lipid metabolism in mice. Mol Nutr Food Res. 2014; 58(7):1502-12. DOI: 10.1002/mnfr.201300726. View

3.
Hajifathalian K, Sagvand B, McCullough A . Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. Hepatology. 2018; 70(2):511-521. PMC: 6380949. DOI: 10.1002/hep.30226. View

4.
Scorletti E, Byrne C . Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr. 2013; 33:231-48. DOI: 10.1146/annurev-nutr-071812-161230. View

5.
Sinha R, Cross A, Graubard B, Leitzmann M, Schatzkin A . Meat intake and mortality: a prospective study of over half a million people. Arch Intern Med. 2009; 169(6):562-71. PMC: 2803089. DOI: 10.1001/archinternmed.2009.6. View